US Stock MarketDetailed Quotes
BMEA Biomea Fusion
- 3.880
- 0.0000.00%
Close Dec 31 16:00 ET
- 3.810
- -0.070-1.80%
Post 20:01 ET
140.61MMarket Cap-0.97P/E (TTM)
3.960High3.800Low733.82KVolume3.900Open3.880Pre Close2.84MTurnover3.27%Turnover RatioLossP/E (Static)36.24MShares20.21052wk High1.85P/B87.13MFloat Cap3.61052wk Low--Dividend TTM22.46MShs Float43.690Historical High--Div YieldTTM4.12%Amplitude2.840Historical Low3.871Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Biomea Fusion Stock Forum
Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient population
Icovamenib was well-tolerated, with no adverse-event related discontinuations, no hypoglycemic events and no serious adverse events
Yet all the analysts are giving target price from a low 11$ to a 50/60 and above.
What's your take?
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
$KULR Technology (KULR.US)$ PR 12/17: Signs Service Agreement to Launch KULR ONE Space Battery. COH $13.4M good for 9 months✅
$Wearable Devices (WLDS.US)$ PR 12/17:...
Biomea Fusion Inc - Icovamenib Meets Primary Endpoint With Significant Reduction in Hba1C
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes
Tuesday, 17th December at 8:10 am
• Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient population
• Best response achieved in target, beta-cell deficient patients on one or more antidiabetic agents at baseline, showing a placeb...
No comment yet